ag凯发k8真人娱乐注册开户

Free Lonza webinar that features bioprocess optimization through automated, aseptic sampling for bioreactors enabling control of product quality attributes and accelerated development times.

Basel, Switzerland, 9 June 2020 – On 23 June, Lonza will host a free 60-minute webinar on how to gain control of bioprocesses through automated, aseptic sampling of bioreactors. Dr. Clint Pepper, Director, MAST® Products, will present three case studies demonstrating cost savings and enhanced throughput and Product Quality Attribute (PQA) optimization using the MAST® Aseptic Sampling System, while maintaining bioreactor integrity.

One of the greatest challenges for bioprocess optimization by pharmaceutical companies is to obtain and analyze reliable aseptic samples from bioreactors. Automated aseptic sampling technology not only maintains bioreactor integrity, but also significantly increases visibility to results, improving bioprocess control and resulting in faster development and transfer to manufacturing.

More information about attending the webinar is availablehere.

Bioreactor Aseptic Sampling and Process Control

Presenter: Clint Pepper
Moderator: Joseph Camp, Senior Scientific Support Specialist, Lonza Bioscience Solutions
Tuesday, 23 June 2020
8 AM PDT (Los Angeles)
11 AM EDT (New York)
4 PM BST (London)
5 PM CEST (Berlin)

Further information can be found onLonza’s MAST® Aseptic Sampling web page. By registering interest in the webinar, participants will also receive a link once it is available to view the webinar “on demand” via the Lonza website.

More information about Lonza’s upcoming and on-demand webinars is available here:www.lonza.com/webinars

About Lonza
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more atwww.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.